Welcome to our dedicated page for AstraZeneca SEC filings (Ticker: AZNCF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AZNCF SEC filings page on Stock Titan provides access to AstraZeneca PLC regulatory disclosures as furnished to the U.S. Securities and Exchange Commission. AstraZeneca uses Form 6-K reports to share information on clinical trial results, regulatory milestones and portfolio updates for its prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Recent 6-K filings show the depth of information available to investors and researchers. One report details the KOMET Phase III trial of Koselugo (selumetinib) in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas, supporting a positive opinion from the European Medicines Agency’s CHMP. Another filing summarises the WAYPOINT Phase III trial of Tezspire (tezepelumab) in chronic rhinosinusitis with nasal polyps, including co-primary endpoints on nasal polyp score and nasal congestion.
Additional 6-Ks provide high-level data from the TULIP-SC Phase III trial of Saphnelo (anifrolumab) in systemic lupus erythematosus and an update on the RESOLUTE Phase III trial of Fasenra (benralizumab) in chronic obstructive pulmonary disease. These documents also restate AstraZeneca’s standard company description, outlining its global footprint, therapeutic focus and Respiratory & Immunology franchise.
On Stock Titan, users can review these filings as they are made available from EDGAR and use AI-powered summaries to understand the key points of each document, such as trial design, primary and secondary endpoints, safety profiles and regulatory implications, without reading every technical detail.
ASTRAZENECA PLC officer Mani Sharma filed an initial insider ownership report, listing current equity and award holdings in the company. Sharma directly holds 31,153.4659 ordinary shares, plus equity awards that may convert into additional shares over time.
The filing shows 2,996.3080 restricted stock units, each representing a right to receive one ordinary share that vests on November 16, 2028, with shares to be delivered on November 17, 2028. There are also 31.2970 dividend equivalent rights, which accrue on these RSUs and convert into ordinary shares on the same vesting date.
In addition, Sharma holds an employee stock option covering 195 ordinary shares at an exercise price of $123.9800 per share, exercisable from December 1, 2028 until June 1, 2029. The exercise price is originally denominated at GBP93.64, with the reported dollar value based on a stated exchange rate.
ASTRAZENECA PLC officer Mani Sharma filed an initial insider ownership report, listing current equity and award holdings in the company. Sharma directly holds 31,153.4659 ordinary shares, plus equity awards that may convert into additional shares over time.
The filing shows 2,996.3080 restricted stock units, each representing a right to receive one ordinary share that vests on November 16, 2028, with shares to be delivered on November 17, 2028. There are also 31.2970 dividend equivalent rights, which accrue on these RSUs and convert into ordinary shares on the same vesting date.
In addition, Sharma holds an employee stock option covering 195 ordinary shares at an exercise price of $123.9800 per share, exercisable from December 1, 2028 until June 1, 2029. The exercise price is originally denominated at GBP93.64, with the reported dollar value based on a stated exchange rate.
AstraZeneca PLC reports that its immunotherapy Imfinzi (durvalumab), combined with standard FLOT chemotherapy, has been approved in the EU as the first perioperative immunotherapy for adults with resectable Stage II-IVA gastric and gastroesophageal junction cancers. The regimen is given before and after surgery, then continued as Imfinzi alone.
The approval is based on the Phase III MATTERHORN trial, where Imfinzi plus FLOT cut the risk of disease progression, recurrence or death by 29% (event-free survival HR 0.71; p<0.001) versus chemotherapy alone, with higher one- and two-year event-free rates. Final overall survival data showed a 22% reduction in the risk of death (HR 0.78; p=0.021), with an estimated 69% of patients alive at three years compared with 62% on chemotherapy alone. The safety profile and surgery completion rates were similar between arms.
AstraZeneca PLC reports that its immunotherapy Imfinzi (durvalumab), combined with standard FLOT chemotherapy, has been approved in the EU as the first perioperative immunotherapy for adults with resectable Stage II-IVA gastric and gastroesophageal junction cancers. The regimen is given before and after surgery, then continued as Imfinzi alone.
The approval is based on the Phase III MATTERHORN trial, where Imfinzi plus FLOT cut the risk of disease progression, recurrence or death by 29% (event-free survival HR 0.71; p<0.001) versus chemotherapy alone, with higher one- and two-year event-free rates. Final overall survival data showed a 22% reduction in the risk of death (HR 0.78; p=0.021), with an estimated 69% of patients alive at three years compared with 62% on chemotherapy alone. The safety profile and surgery completion rates were similar between arms.
AstraZeneca PLC has published its Notice of Annual General Meeting 2026 and shareholders’ circular and is dispatching them to shareholders. The digitally-enabled AGM will be held on 9 April 2026 at 14:30 (BST).
Shareholders will vote on receiving the 2025 accounts, confirming 2025 interim dividends, appointing KPMG LLP as auditor, re-electing directors, approving the remuneration report, renewing authority for the 2020 Performance Share Plan French appendix, authorising political donations, allotting shares, disapplying pre-emption rights, authorising share buybacks, and reducing the notice period for general meetings. The Notice and related documents are available on AstraZeneca’s website and via the UK National Storage Mechanism.
AstraZeneca PLC has published its Notice of Annual General Meeting 2026 and shareholders’ circular and is dispatching them to shareholders. The digitally-enabled AGM will be held on 9 April 2026 at 14:30 (BST).
Shareholders will vote on receiving the 2025 accounts, confirming 2025 interim dividends, appointing KPMG LLP as auditor, re-electing directors, approving the remuneration report, renewing authority for the 2020 Performance Share Plan French appendix, authorising political donations, allotting shares, disapplying pre-emption rights, authorising share buybacks, and reducing the notice period for general meetings. The Notice and related documents are available on AstraZeneca’s website and via the UK National Storage Mechanism.
AstraZeneca PLC reported that Chief Executive Officer Pascal Soriot received ordinary shares following the vesting of a long-term incentive award under the AstraZeneca Performance Share Plan (AZPSP).
The AZPSP award, granted on 5 March 2021 with a three-year performance period and subsequent two-year holding period, vested on its fifth anniversary. Application of the original performance conditions led to 88% of the award vesting and the remainder lapsing. After dividend reinvestment and withholding of shares to cover tax obligations, Soriot acquired 101,495 ordinary shares on 5 March 2026 for nil consideration. For tax purposes, the fair market value at vest was 15,088 pence per share, based on the closing price on the previous trading day.
AstraZeneca PLC reported that Chief Executive Officer Pascal Soriot received ordinary shares following the vesting of a long-term incentive award under the AstraZeneca Performance Share Plan (AZPSP).
The AZPSP award, granted on 5 March 2021 with a three-year performance period and subsequent two-year holding period, vested on its fifth anniversary. Application of the original performance conditions led to 88% of the award vesting and the remainder lapsing. After dividend reinvestment and withholding of shares to cover tax obligations, Soriot acquired 101,495 ordinary shares on 5 March 2026 for nil consideration. For tax purposes, the fair market value at vest was 15,088 pence per share, based on the closing price on the previous trading day.
AstraZeneca PLC reports the issuance by its subsidiary AstraZeneca Finance LLC of three new U.S. dollar fixed rate note tranches, fully and unconditionally guaranteed by AstraZeneca PLC. These consist of $650,000,000 4.000% notes due 2031, $600,000,000 4.300% notes due 2033, and $750,000,000 4.600% notes due 2036.
The company is furnishing this information so the related underwriting, pricing, officer certificates, and legal opinions can be incorporated into its existing shelf registration statement on Form F-3.
AstraZeneca PLC reports the issuance by its subsidiary AstraZeneca Finance LLC of three new U.S. dollar fixed rate note tranches, fully and unconditionally guaranteed by AstraZeneca PLC. These consist of $650,000,000 4.000% notes due 2031, $600,000,000 4.300% notes due 2033, and $750,000,000 4.600% notes due 2036.
The company is furnishing this information so the related underwriting, pricing, officer certificates, and legal opinions can be incorporated into its existing shelf registration statement on Form F-3.
AstraZeneca PLC reports its current voting share capital. As at 28 February 2026, the company has 1,550,966,708 issued ordinary shares of US$0.25 each with voting rights, and no shares held in treasury. This means the total number of voting rights is 1,550,966,708.
Shareholders can use this total voting rights figure as the denominator when calculating whether they must notify the UK Financial Conduct Authority of holdings or changes in their interest under the Disclosure and Transparency Rules.
AstraZeneca PLC reports its current voting share capital. As at 28 February 2026, the company has 1,550,966,708 issued ordinary shares of US$0.25 each with voting rights, and no shares held in treasury. This means the total number of voting rights is 1,550,966,708.
Shareholders can use this total voting rights figure as the denominator when calculating whether they must notify the UK Financial Conduct Authority of holdings or changes in their interest under the Disclosure and Transparency Rules.
AstraZeneca PLC has priced a $2bn global bond offering through its wholly owned subsidiary AstraZeneca Finance LLC. The bonds are issued in three fixed-rate tranches registered with the U.S. SEC and are fully and unconditionally guaranteed by AstraZeneca.
The tranches comprise $0.65bn of notes with a 4.000% coupon maturing on 2 March 2031, $0.60bn with a 4.300% coupon maturing on 2 March 2033, and $0.75bn with a 4.600% coupon maturing on 2 March 2036.
AstraZeneca expects to use the net proceeds for general corporate purposes, which may include refinancing existing debt. The company states that this bond issuance does not impact its financial guidance for 2026.
AstraZeneca PLC has priced a $2bn global bond offering through its wholly owned subsidiary AstraZeneca Finance LLC. The bonds are issued in three fixed-rate tranches registered with the U.S. SEC and are fully and unconditionally guaranteed by AstraZeneca.
The tranches comprise $0.65bn of notes with a 4.000% coupon maturing on 2 March 2031, $0.60bn with a 4.300% coupon maturing on 2 March 2033, and $0.75bn with a 4.600% coupon maturing on 2 March 2036.
AstraZeneca expects to use the net proceeds for general corporate purposes, which may include refinancing existing debt. The company states that this bond issuance does not impact its financial guidance for 2026.
AstraZeneca PLC has filed its 2025 Annual Report on Form 20-F with the US Securities and Exchange Commission. The report can be viewed on both the SEC website and the company’s own site, giving investors access to detailed audited financial and business information.
The company will provide any security holder with a hard copy of its complete audited financial statements free of charge upon request through its Company Secretary in Cambridge, UK.
AstraZeneca PLC has filed its 2025 Annual Report on Form 20-F with the US Securities and Exchange Commission. The report can be viewed on both the SEC website and the company’s own site, giving investors access to detailed audited financial and business information.
The company will provide any security holder with a hard copy of its complete audited financial statements free of charge upon request through its Company Secretary in Cambridge, UK.
AstraZeneca PLC has filed its Form 20‑F annual report for the year ended 31 December 2025, summarising its global operations, risks and product portfolio. The company lists ordinary shares and multiple long-dated notes on the New York Stock Exchange and reports 1,550,907,927 ordinary shares outstanding at year-end.
The filing incorporates by reference the detailed 2025 Annual Report, while this document highlights extensive risk factors across product development, pricing, supply chain, cybersecurity, AI, legal and sustainability areas. It presents a broad late‑stage pipeline in oncology, cardiovascular, respiratory and rare disease, with numerous Phase III trials and anticipated data readouts beyond 2026.
AstraZeneca also discloses patent expiry ranges for key marketed medicines such as Tagrisso, Imfinzi, Farxiga, Calquence, Ultomiris and others, flagging ongoing generic challenges and potential ‘at risk’ launches. Selected product sales data show Tagrisso at $7,254 million and Farxiga/Forxiga at $6,670 million in 2025, underlining oncology and CVRM as major revenue drivers.
AstraZeneca PLC has filed its Form 20‑F annual report for the year ended 31 December 2025, summarising its global operations, risks and product portfolio. The company lists ordinary shares and multiple long-dated notes on the New York Stock Exchange and reports 1,550,907,927 ordinary shares outstanding at year-end.
The filing incorporates by reference the detailed 2025 Annual Report, while this document highlights extensive risk factors across product development, pricing, supply chain, cybersecurity, AI, legal and sustainability areas. It presents a broad late‑stage pipeline in oncology, cardiovascular, respiratory and rare disease, with numerous Phase III trials and anticipated data readouts beyond 2026.
AstraZeneca also discloses patent expiry ranges for key marketed medicines such as Tagrisso, Imfinzi, Farxiga, Calquence, Ultomiris and others, flagging ongoing generic challenges and potential ‘at risk’ launches. Selected product sales data show Tagrisso at $7,254 million and Farxiga/Forxiga at $6,670 million in 2025, underlining oncology and CVRM as major revenue drivers.